This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liotta, L. A. Articles by Garbisa, S. Search for Related Content PubMed PubMed Citation Articles by Liotta, L. A. Articles by Garbisa, S.

Effect of Plasminogen Activator (Urokinase), Plasmin, and Thrombin on Glycoprotein and Collagenous Components of Basement Membrane

Laboratories of Pathophysiology [L. A. L., R. B., G. P. S.], and Immunodiagnosis [R. H. G.], National Cancer Institute, and National Institute of Dental Research, [V. P. T.], NIH, Bethesda, Maryland 20205, and Institute of Histology [S. G.], University of Padova, Italy

Tumor cells traverse basement membranes (BM) during the stages of the metastatic process. Penetration of the BM may involve proteolysis by enzymes directly or indirectly associated with tumor cells. This study evaluated the role of the serine proteases urokinase (plasminogen activator), plasmin, and another regulatory protease, -thrombin, in the degradation of the BM. Homogeneously pure enzyme preparations were incubated with isolated components of BM and with whole human amnion BM. The BM components consisted of acid-extracted type IV collagen, pepsin fragments of collagen type IV, laminin, and fibronectin. Collagen type V (AB) associated with the peri-BM zone was also studied. The purity of the enzymes was verified by gel electrophoresis and inhibitor studies. Digestion of the BM components was performed at 25° using matched activity for the different enzymes. Urokinase failed to significantly degrade fibronectin or any of the other BM components. Under the same 25° (native) conditions, plasmin and thrombin cleaved fibronectin and laminin into multiple specific fragments but did not produce a major cleavage of acid-extracted type IV collagen, pepsinized type IV collagen, or AB (type V) collagen. -Thrombin selectively degraded only the m.w. 400,000 chain of laminin, whereas plasmin degraded both of the laminin chains. Digestion of laminin by the serine proteases was time and concentration dependent, as verified by a new degradation assay using [¹⁴C]laminin. A variety of normal and neoplastic cells were tested for the presence of laminin-degrading proteases. Macrophages, polymorphonuclear leukocytes, and metastatic tumor cells contained a significant laminin-degrading activity. The activity was enhanced by the addition of plasminogen. Type V collagen was cleaved by thrombin and plasmin at 35° but not at temperatures below 33°. Following treatment of whole-amnion BM with any of these enzymes, electron microscopy demonstrated preservation of the lamina densa. Immunohistology studies indicated that laminin, but not type IV collagen, was removed from the whole BM by plasmin treatment. The results suggest that these BM components are poor substrates for plasminogen activators and that plasmin alone is not sufficient to completely degrade the whole BM. Plasmin, generated through the action of plasminogen activator, may play a significant role in the degradation of noncollagenous components of the BM.

¹ To whom requests for reprints should be addressed.

Received 12/17/80. Accepted 8/11/81.

This article has been cited by other articles:

				J. Gonzalez, J. Klein, S. D. Chauhan, E. Neau, D. Calise, C. Nevoit, R. Chaaya, M. Miravete, C. Delage, J.-L. Bascands, et al. Delayed Treatment with Plasminogen Activator Inhibitor-1 Decoys Reduces Tubulointerstitial Fibrosis Experimental Biology and Medicine, December 1, 2009; 234(12): 1511 - 1518. [Abstract] [Full Text] [PDF]

				Y. Huang, W. A. Border, D. A. Lawrence, and N. A. Noble Mechanisms underlying the antifibrotic properties of noninhibitory PAI-1 (PAI-1R) in experimental nephritis Am J Physiol Renal Physiol, October 1, 2009; 297(4): F1045 - F1054. [Abstract] [Full Text] [PDF]

				H. Yuan, K. M. Vance, C. E. Junge, M. T. Geballe, J. P. Snyder, J. R. Hepler, M. Yepes, C.-M. Low, and S. F. Traynelis The Serine Protease Plasmin Cleaves the Amino-terminal Domain of the NR2A Subunit to Relieve Zinc Inhibition of the N-Methyl-D-aspartate Receptors J. Biol. Chem., May 8, 2009; 284(19): 12862 - 12873. [Abstract] [Full Text] [PDF]

				T. L. Ponsioen, M. J. A. van Luyn, R. J. van der Worp, J. C. van Meurs, J. M. M. Hooymans, and L. I. Los Collagen Distribution in the Human Vitreoretinal Interface Invest. Ophthalmol. Vis. Sci., September 1, 2008; 49(9): 4089 - 4095. [Abstract] [Full Text] [PDF]

				C. M. Swaisgood, M. A. Aronica, S. Swaidani, and E. F. Plow Plasminogen Is an Important Regulator in the Pathogenesis of a Murine Model of Asthma Am. J. Respir. Crit. Care Med., August 15, 2007; 176(4): 333 - 342. [Abstract] [Full Text] [PDF]

				M. Narazaki and G. Tosato Conflicting results from clinical observations and murine models: what is the role of plasminogen activators in tumor growth? J Natl Cancer Inst, June 7, 2006; 98(11): 726 - 727. [Full Text] [PDF]

				I. Bergheim, L. Guo, M. A. Davis, I. Duveau, and G. E. Arteel Critical Role of Plasminogen Activator Inhibitor-1 in Cholestatic Liver Injury and Fibrosis J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 592 - 600. [Abstract] [Full Text] [PDF]

				M. Cicek, R. Fukuyama, D. R. Welch, N. Sizemore, and G. Casey Breast Cancer Metastasis Suppressor 1 Inhibits Gene Expression by Targeting Nuclear Factor-{kappa}B Activity Cancer Res., May 1, 2005; 65(9): 3586 - 3595. [Abstract] [Full Text] [PDF]

				A. Uemura, M. Nakamura, S. Kachi, Y. Nishizawa, T. Asami, Y. Miyake, and H. Terasaki Effect of Plasmin on Laminin and Fibronectin During Plasmin-Assisted Vitrectomy Arch Ophthalmol, February 1, 2005; 123(2): 209 - 213. [Abstract] [Full Text] [PDF]

				F. Wang, Z. Wang, X. Sun, F. Wang, X. Xu, and X. Zhang Safety and Efficacy of Dispase and Plasmin in Pharmacologic Vitreolysis Invest. Ophthalmol. Vis. Sci., September 1, 2004; 45(9): 3286 - 3290. [Abstract] [Full Text] [PDF]

				M. R. Gyetko, D. Aizenberg, and L. Mayo-Bond Urokinase-deficient and urokinase receptor-deficient mice have impaired neutrophil antimicrobial activation in vitro J. Leukoc. Biol., September 1, 2004; 76(3): 648 - 656. [Abstract] [Full Text] [PDF]

				A. Csutak, D. M. Silver, J. Tozser, Z. Hassan, and A. Berta Urokinase-Type Plasminogen Activator to Prevent Haze after Photorefractive Keratectomy, and Pregnancy as a Risk Factor for Haze in Rabbits Invest. Ophthalmol. Vis. Sci., May 1, 2004; 45(5): 1329 - 1333. [Abstract] [Full Text] [PDF]

				A. Furuyama and K. Mochitate Hepatocyte growth factor inhibits the formation of the basement membrane of alveolar epithelial cells in vitro Am J Physiol Lung Cell Mol Physiol, May 1, 2004; 286(5): L939 - L946. [Abstract] [Full Text] [PDF]

				B.-Q. Zhao, Y. Ikeda, H. Ihara, T. Urano, W. Fan, S. Mikawa, Y. Suzuki, K. Kondo, K. Sato, N. Nagai, et al. Essential role of endogenous tissue plasminogen activator through matrix metalloproteinase 9 induction and expression on heparin-produced cerebral hemorrhage after cerebral ischemia in mice Blood, April 1, 2004; 103(7): 2610 - 2616. [Abstract] [Full Text] [PDF]

				A. Gandorfer, M. Rohleder, C. Sethi, D. Eckle, U. Welge-Lussen, A. Kampik, P. Luthert, and D. Charteris Posterior Vitreous Detachment Induced by Microplasmin Invest. Ophthalmol. Vis. Sci., February 1, 2004; 45(2): 641 - 647. [Abstract] [Full Text] [PDF]

				T. Pfefferkorn and G. A. Rosenberg Closure of the Blood-Brain Barrier by Matrix Metalloproteinase Inhibition Reduces rtPA-Mediated Mortality in Cerebral Ischemia With Delayed Reperfusion Stroke, August 1, 2003; 34(8): 2025 - 2030. [Abstract] [Full Text] [PDF]

				H. Ha and H. B. Lee Reactive Oxygen Species and Matrix Remodeling in Diabetic Kidney J. Am. Soc. Nephrol., August 1, 2003; 14(90003): S246 - 249. [Abstract] [Full Text] [PDF]

				K. Kallenbach, H. A. Fernandez, G. Seghezzi, F. G. Baumann, S. Patel, E. A. Grossi, A. C. Galloway, and P. Mignatti A Quantitative In Vitro Model of Smooth Muscle Cell Migration Through the Arterial Wall Using the Human Amniotic Membrane Arterioscler Thromb Vasc Biol, June 1, 2003; 23(6): 1008 - 1013. [Abstract] [Full Text] [PDF]

				A. Collen, R. Hanemaaijer, F. Lupu, P. H. A. Quax, N. van Lent, J. Grimbergen, E. Peters, P. Koolwijk, and V. W. M. van Hinsbergh Membrane-type matrix metalloproteinase-mediated angiogenesis in a fibrin-collagen matrix Blood, March 1, 2003; 101(5): 1810 - 1817. [Abstract] [Full Text] [PDF]

				D. D. Boyd, S.-J. Kim, H. Wang, T. R. Jones, and G. E. Gallick A Urokinase-Derived Peptide (A6) Increases Survival of Mice Bearing Orthotopically Grown Prostate Cancer and Reduces Lymph Node Metastasis Am. J. Pathol., February 1, 2003; 162(2): 619 - 626. [Abstract] [Full Text] [PDF]

				F. Besta, S. Massberg, K. Brand, E. Muller, S. Page, S. Gruner, M. Lorenz, K. Sadoul, W. Kolanus, E. Lengyel, et al. Role of {beta}3-endonexin in the regulation of NF-{kappa}B-dependent expression of urokinase-type plasminogen activator receptor J. Cell Sci., October 15, 2002; 115(20): 3879 - 3888. [Abstract] [Full Text] [PDF]

				S. Vejda, C. Posovszky, S. Zelzer, B. Peter, E. Bayer, D. Gelbmann, R. Schulte-Hermann, and C. Gerner Plasma from Cancer Patients Featuring a Characteristic Protein Composition Mediates Protection against Apoptosis Mol. Cell. Proteomics, May 1, 2002; 1(5): 387 - 393. [Abstract] [Full Text] [PDF]

				B.-Q. Zhao, Y. Suzuki, K. Kondo, Y. Ikeda, and K. Umemura Combination of a Free Radical Scavenger and Heparin Reduces Cerebral Hemorrhage After Heparin Treatment in a Rabbit Middle Cerebral Artery Occlusion Model Stroke, September 1, 2001; 32(9): 2157 - 2163. [Abstract] [Full Text] [PDF]

				M. A. Helenius, O. R. Saramaki, M. J. Linja, T. L. J. Tammela, and T. Visakorpi Amplification of Urokinase Gene in Prostate Cancer Cancer Res., July 1, 2001; 61(14): 5340 - 5344. [Abstract] [Full Text] [PDF]

				S. Hapke, M. Gawaz, K. Dehne, J. Köhler, J. F. Marshall, H. Graeff, M. Schmitt, U. Reuning, and E. Lengyel {beta}3A-Integrin Downregulates the Urokinase-Type Plasminogen Activator Receptor (u-PAR) through a PEA3/ets Transcriptional Silencing Element in the u-PAR Promoter Mol. Cell. Biol., March 15, 2001; 21(6): 2118 - 2132. [Abstract] [Full Text]

				A Gandorfer, E Putz, U Welge-LüBen, M Grüterich, M Ulbig, and A Kampik Ultrastructure of the vitreoretinal interface following plasmin assisted vitrectomy Br J Ophthalmol, January 1, 2001; 85(1): 6 - 10. [Abstract] [Full Text]

				H. Tapper and H. Herwald Modulation of hemostatic mechanisms in bacterial infectious diseases Blood, October 1, 2000; 96(7): 2329 - 2337. [Full Text] [PDF]

				A. F. Drew, H. L. Schiman, K. W. Kombrinck, T. H. Bugge, J. L. Degen, and A. H. Kaufman Persistent Corneal Haze after Excimer Laser Photokeratectomy in Plasminogen-Deficient Mice Invest. Ophthalmol. Vis. Sci., January 1, 2000; 41(1): 67 - 72. [Abstract] [Full Text]

				J. L. Coleman, E. J. Roemer, and J. L. Benach Plasmin-Coated Borrelia burgdorferi Degrades Soluble and Insoluble Components of the Mammalian Extracellular Matrix Infect. Immun., August 1, 1999; 67(8): 3929 - 3936. [Abstract] [Full Text] [PDF]

				S. Ried, C. Jager, M. Jeffers, G. F. Vande Woude, H. Graeff, M. Schmitt, and E. Lengyel Activation Mechanisms of the Urokinase-type Plasminogen Activator Promoter by Hepatocyte Growth Factor/Scatter Factor J. Biol. Chem., June 4, 1999; 274(23): 16377 - 16386. [Abstract] [Full Text] [PDF]

				D. Tong, C. Schneeberger, K. Czerwenka, R. K. Schmutzler, P. Speiser, E. Kucera, N. Concin, E. Kubista, S. Leodolter, and R. Zeillinger Messenger RNA Determination of Estrogen Receptor, Progesterone Receptor, pS2, and Plasminogen Activator Inhibitor-1 by Competitive Reverse Transcription-Polymerase Chain Reaction in Human Breast Cancer Clin. Cancer Res., June 1, 1999; 5(6): 1497 - 1502. [Abstract] [Full Text] [PDF]

				G. J DEL ZOPPO, R. VON KUMMER, and G. F HAMANN Ischaemic damage of brain microvessels: inherent risks for thrombolytic treatment in stroke J. Neurol. Neurosurg. Psychiatry, July 1, 1998; 65(1): 1 - 9. [Full Text]

				R. P. Kitson, P. M. Appasamy, U. Nannmark, P. Albertsson, M. K. Gabauer, and R. H. Goldfarb Matrix Metalloproteinases Produced by Rat IL-2-Activated NK Cells J. Immunol., May 1, 1998; 160(9): 4248 - 4253. [Abstract] [Full Text] [PDF]

				F. A. Day and D. A. Neufeld Use of Enzyme Overlay Membranes to Survey Proteinase Activity in Frozen Sections: Cathepsin-like and Plasmin-like Activity in Regenerating Newt Limbs J. Histochem. Cytochem., June 1, 1997; 45(6): 779 - 784. [Abstract] [Full Text] [PDF]

				T. A. Hembrough, L. Li, and S. L. Gonias Cell-surface Cytokeratin 8Is the Major Plasminogen Receptor on Breast Cancer Cells and Is Required for the Accelerated Activation of Cell-associated Plasminogen by Tissue-type Plasminogen Activator J. Biol. Chem., October 11, 1996; 271(41): 25684 - 25691. [Abstract] [Full Text] [PDF]

				P. F. Dunn, K. D. Newman, M. Jones, I. Yamada, V. Shayani, R. Virmani, and D. A. Dichek Seeding of Vascular Grafts With Genetically Modified Endothelial Cells : Secretion of Recombinant TPA Results in Decreased Seeded Cell Retention In Vitro and In Vivo Circulation, April 1, 1996; 93(7): 1439 - 1446. [Abstract] [Full Text]

				E. Lengyel, E. Stepp, R. Gum, and D. Boyd Involvement of a Mitogen-activated Protein Kinase Signaling Pathway in the Regulation of Urokinase Promoter Activity by c-Ha-ras J. Biol. Chem., September 29, 1995; 270(39): 23007 - 23012. [Abstract] [Full Text] [PDF]

				T. Hembrough, J Vasudevan, M. Allietta, W. Glass, and S. Gonias A cytokeratin 8-like protein with plasminogen-binding activity is present on the external surfaces of hepatocytes, HepG2 cells and breast carcinoma cell lines J. Cell Sci., January 3, 1995; 108(3): 1071 - 1082. [Abstract] [PDF]

				T. C. Verstraeten, C. Chapman, M. Hartzer, B. S. Winkler, M. T. Trese, and G. A. Williams Pharmacologic Induction of Posterior Vitreous Detachment in the Rabbit Arch Ophthalmol, June 1, 1993; 111(6): 849 - 854. [Abstract] [PDF]

				P. McGuire and S. Alexander Inhibition of urokinase synthesis and cell surface binding alters the motile behavior of embryonic endocardial-derived mesenchymal cells in vitro Development, January 7, 1993; 118(3): 931 - 939. [Abstract] [PDF]

				S. Liu, T. H. Bugge, and S. H. Leppla Targeting of Tumor Cells by Cell Surface Urokinase Plasminogen Activator-dependent Anthrax Toxin J. Biol. Chem., May 18, 2001; 276(21): 17976 - 17984. [Abstract] [Full Text] [PDF]